1. | lovejo34 | |
2. | westtexaspeddler | |
3. | flemingo7949 | |
4. | jhwexec | |
5. | orbiter495 |
1. | lovejo34 | |
2. | westtexaspeddler | |
3. | flemingo7949 | |
4. | jhwexec | |
5. | orbiter495 |
1. | lovejo34 02/01/2018 $11 one day |
2. | orbiter495 08/08/2018 ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update |
3. | westtexaspeddler 02/01/2018 Files for $200 mln mixed securities shelf offering |
4. | lovejo34 06/18/2018 ugg, offering |
5. | westtexaspeddler 06/18/2018 Reaches primary and secondary enpoints for EDELWEISS Phase 2b clinical trial of linzagolix |
6. | lovejo34 02/27/2018 ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF |
7. | lovejo34 02/05/2018 H.C. Wainwright & Co. reiterates Buy rating, $25 PT |
8. | westtexaspeddler 10/04/2018 ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET) |
9. | lovejo34 06/18/2018 ObsEva Announces Launch of Proposed Follow-on Public Offering |